BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halford WP. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? Expert Rev Vaccines 2014;13:691-710. [PMID: 24837838 DOI: 10.1586/14760584.2014.910121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Ramsey NLM, Visciano M, Hunte R, Loh LN, Burn Aschner C, Jacobs WR Jr, Herold BC. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus. J Virol 2020;94:e00335-20. [PMID: 32295919 DOI: 10.1128/JVI.00335-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
2 Royer DJ, Montgomery ML, Carr DJ. Mucosal Regulatory System for Balanced Ocular Immunity. Mucosal Vaccines 2020. [DOI: 10.1016/b978-0-12-811924-2.00017-1] [Reference Citation Analysis]
3 Bandara HMHN, Samaranayake LP. Viral, bacterial, and fungal infections of the oral mucosa: Types, incidence, predisposing factors, diagnostic algorithms, and management. Periodontol 2000 2019;80:148-76. [PMID: 31090135 DOI: 10.1111/prd.12273] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
4 Royer DJ, Hendrix JF, Larabee CM, Reagan AM, Sjoelund VH, Robertson DM, Carr DJJ. Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection. Mucosal Immunol 2019;12:827-39. [PMID: 30670763 DOI: 10.1038/s41385-019-0131-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
5 Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Vaccine 2019;37:61-8. [DOI: 10.1016/j.vaccine.2018.11.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
6 Davido DJ, Tu EM, Wang H, Korom M, Gazquez Casals A, Reddy PJ, Mostafa HH, Combs B, Haenchen SD, Morrison LA. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease. J Virol 2018;92:e01036-18. [PMID: 29950407 DOI: 10.1128/JVI.01036-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang X, Jiang Q, Xu X, Wang Y, Liu L, Lian Y, Li H, Wang L, Zhang Y, Jiang G, Zeng J, Zhang H, Han JJ, Li Q. Immune mechanisms induced by an HSV-1 mutant strain: Discrepancy analysis of the immune system gene profile in comparison with a wild-type strain. Vaccine 2018;36:2394-402. [PMID: 29602705 DOI: 10.1016/j.vaccine.2018.03.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Royer DJ, Carr DJJ. Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?". J Virol 2017;91:e01464-17. [PMID: 29138328 DOI: 10.1128/JVI.01464-17] [Reference Citation Analysis]
9 Royer DJ, Carr MM, Gurung HR, Halford WP, Carr DJJ. The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa. J Immunol 2017;199:1898-911. [PMID: 28760885 DOI: 10.4049/jimmunol.1700316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Royer DJ, Carr MM, Chucair-Elliott AJ, Halford WP, Carr DJJ. Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice. J Virol 2017;91:e02342-16. [PMID: 28122977 DOI: 10.1128/JVI.02342-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model. Viral Immunol 2017;30:178-95. [PMID: 28085634 DOI: 10.1089/vim.2016.0136] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Royer DJ, Conrady CD, Carr DJ. Herpesvirus-Associated Lymphadenitis Distorts Fibroblastic Reticular Cell Microarchitecture and Attenuates CD8 T Cell Responses to Neurotropic Infection in Mice Lacking the STING-IFNα/β Defense Pathways. J Immunol 2016;197:2338-52. [PMID: 27511736 DOI: 10.4049/jimmunol.1600574] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
13 Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine 2016;34:2216-24. [PMID: 27002499 DOI: 10.1016/j.vaccine.2016.03.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
14 Halford WP, Geltz J, Messer RJ, Hasenkrug KJ. Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2. PLoS One 2015;10:e0145228. [PMID: 26670699 DOI: 10.1371/journal.pone.0145228] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
15 Boukhvalova M, McKay J, Mbaye A, Sanford-Crane H, Blanco JC, Huber A, Herold BC. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model. J Virol 2015;89:9825-40. [PMID: 26178984 DOI: 10.1128/JVI.01387-15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
16 Suazo PA, Ibañez FJ, Retamal-Díaz AR, Paz-Fiblas MV, Bueno SM, Kalergis AM, González PA. Evasion of early antiviral responses by herpes simplex viruses. Mediators Inflamm 2015;2015:593757. [PMID: 25918478 DOI: 10.1155/2015/593757] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
17 Geltz JJ, Gershburg E, Halford WP. Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. PLoS One 2015;10:e0116091. [PMID: 25658852 DOI: 10.1371/journal.pone.0116091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
18 Royer DJ, Cohen A, Carr D. The Current State of Vaccine Development for Ocular HSV-1 Infection. Expert Rev Ophthalmol 2015;10:113-26. [PMID: 25983856 DOI: 10.1586/17469899.2015.1004315] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
19 McAllister SC, Schleiss MR. Prospects and perspectives for development of a vaccine against herpes simplex virus infections. Expert Rev Vaccines 2014;13:1349-60. [PMID: 25077372 DOI: 10.1586/14760584.2014.932694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]